DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Generic Name: entacapone

Summary for Generic Name: entacapone

Tradenames:2
Patents:2
Applicants:4
NDAs:4
Drug Master File Entries: see list18
Suppliers: see list9
Therapeutic Class:Antiparkinson Agents
Formulation / Manufacturing:see details

Pharmacology for Ingredient: entacapone

Clinical Trials for: entacapone

Augmenting Effects of L-DOPS With Carbidopa and Entacapone
Status: Terminated Condition: Parkinson Disease; Multiple System Atrophy; Autonomic Nervous System Diseases

COMT Polymorphism and Entacapone Efficacy
Status: Completed Condition: Parkinson's Disease

Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone in Healthy Volunteers
Status: Completed Condition: Healthy

Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone in Healthy Volunteers
Status: Completed Condition: Healthy

Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone in Healthy Volunteers
Status: Completed Condition: Healthy

Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone Under Fasting Conditions in Healthy Volunteers
Status: Completed Condition: Healthy

Pilot Study of Entacapone for Methamphetamine Abuse
Status: Recruiting Condition: Methamphetamine Dependence

Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off
Status: Terminated Condition: Parkinson's Disease

Efficacy of Levodopa/Carbidopa/Entacapone vs Levodopa/Carbidopa in Parkinson's Disease Patients With Early Wearing-off
Status: Completed Condition: Parkinson's Disease

Entacapone Augmentation for Schizophrenia
Status: Completed Condition: Schizophrenia

Courtesy of ClinicalTrials.org
See more clinical trials for this drug

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Wockhardt Ltd
ENTACAPONE
entacapone
TABLET;ORAL078941Aug 16, 2012RXNo<disabled>
Sun Pharma Global
ENTACAPONE
entacapone
TABLET;ORAL090690Jul 16, 2012RXNo<disabled>
Mylan Pharms Inc
ENTACAPONE
entacapone
TABLET;ORAL202394May 13, 2013RXNo<disabled>
Orion Pharma
COMTAN
entacapone
TABLET;ORAL020796Oct 19, 1999RXYes5,446,194<disabled>Y
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc